Australia’s prothrombin complex concentrate (PCC), Prothrombinex-VF, will be changing in 2024 as one of 5 domestic plasma product transitions taking place acros
Xembify, a 20% concentration SCIg product supplied by Grifols Australia, will be available for supply under the national blood arrangements from January 2024.
The Therapeutic Goods Administration (TGA) recently approved a submission from the Australian Red Cross Lifeblood (Lifeblood) to reduce the deferral period for
